CCDC7 Inhibitors
CCDC7 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of the coiled-coil domain containing 7 (CCDC7) protein. The coiled-coil domain is a structural motif that can mediate protein-protein interactions, and proteins like CCDC7 that contain this domain may play a role in various cellular processes such as signal transduction, cell division, and the maintenance of cellular structure. Inhibitors of CCDC7 are expected to bind to this protein, impeding its normal function and interrupting the cellular processes in which it is involved. The precise mechanism of CCDC7 and the pathway it influences are crucial for determining the design and function of these inhibitors. By binding to CCDC7, these inhibitors may alter its interaction with other proteins, potentially affecting signaling pathways critical for cell cycle regulation or structural assembly within the cell. The design of CCDC7 inhibitors takes into account the protein's three-dimensional structure and the specific residues that are critical for its function or its interaction with other proteins.
The development of CCDC7 inhibitors relies heavily on understanding the molecular details of the CCDC7 protein, including its conformational dynamics and its role within the cell. Advanced computational models and high-resolution imaging techniques are often employed to identify potential binding sites and to design molecules that can effectively interact with these sites. Once identified, these inhibitors can be synthesized and tested to confirm their efficacy in disrupting CCDC7 function. Inhibiting CCDC7 can lead to the disruption of its normal biological activity, potentially causing a cascade of effects within the cell due to the protein's involvement in critical cellular functions. While the specific biochemical pathways and cellular processes that CCDC7 inhibitors affect are complex and multifaceted, the overall goal of these compounds is to selectively and effectively inhibit the function of CCDC7 without affecting other proteins or pathways within the cell. This specificity is key to the utility of these inhibitors in research and potential applications where modulation of CCDC7 activity is desired.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which blocks the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can decrease ERK-mediated phosphorylation, potentially leading to reduced activity of CCDC7 if it is downstream or regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway. It prevents phosphorylation and activation of Akt, thereby reducing the survival signals in the cell. If CCDC7 is part of a survival pathway modulated by Akt, LY294002 would lead to a reduction in CCDC7 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which prevents the activation of the MAPK/ERK pathway. If CCDC7's activity is regulated by the MAPK/ERK pathway, U0126 would result in decreased function of CCDC7. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can lead to decreased regulation of cell cycle and inflammatory responses. If CCDC7 plays a role in these processes, SB203580 could reduce its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which alters the JNK signaling pathway that regulates various cellular processes including apoptosis. If CCDC7 is involved in JNK-mediated processes, SP600125 may decrease its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which can lead to decreased protein synthesis and cell proliferation. If CCDC7 is involved in these cellular processes, rapamycin would reduce its functional activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor that targets multiple kinases, including VEGFR and PDGFR. If CCDC7 is associated with pathways involving these kinases, Sorafenib could indirectly decrease its activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor. By blocking EGFR, gefitinib can reduce downstream signaling that might regulate CCDC7 activity, provided CCDC7 is influenced by EGFR signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor that also inhibits PDGFR and c-Kit. If CCDC7 is downstream of these kinases, its activity could be affected by imatinib. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. If CCDC7 is regulated by the PI3K/Akt pathway, wortmannin would lead to a decrease in CCDC7 activity. | ||||||